AstraZeneca targets $80bn revenue by 2030
The company said it aims to achieve this target by registering growth in its current portfolio in biopharmaceuticals, oncology, and rare diseases. The effort also includes the launch
Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money equity value of about $750m.